Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.
Cancer
DRUG: BMS-833923 (XL139)
Incidence of Dose Limiting Toxicity (DLT) and observed adverse events, Within the first 28 days of treatment|Incidence of Dose Limiting Toxicity (DLT) and observed adverse events, Up to 90 days additional treatment period plus 60 days of follow-up
The number of subjects experienced DLT, Within the first 28 days|Maximum observed concentration (Cmax) of BMS-833923 (XL139), Day1 and Day 29|Trough observed concentration (Cmin) of BMS-833923 (XL139), Day1 and Day 29|Time of maximum observed concentration (Tmax) of BMS-833923 (XL139), Day1 and Day 29|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-833923 (XL139), Day1 and Day 29|Effective half-life (T-half,eff) of BMS-833923 (XL139), Day1 and Day 29|Accumulation index (AI) of BMS-833923 (XL139), Day1 and Day 29|Best overall response assessed according to Response evaluation criteria in solid tumors (RECIST) v1.1 criteria, Up to120 days of treatment period
The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.